Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study

BACKGROUND: In the phase III open-label KEYNOTE-426 (NCT02853331) study, first-line pembrolizumab and axitinib improved overall survival (OS) and progression-free survival (PFS) versus sunitinib for metastatic renal cell carcinoma (mRCC). KEYNOTE-426 evaluated patients enrolled from 25 sites in Japa...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamada, Satoshi, Kondoh, Chihiro, Matsubara, Nobuaki, Mizuno, Ryuichi, Kimura, Go, Anai, Satoshi, Tomita, Yoshihiko, Oyama, Masafumi, Masumori, Naoya, Kojima, Takahiro, Matsumoto, Hiroaki, Chen, Mei, Li, Mengran, Matsuda, Kenji, Tanaka, Yoshinobu, Rini, Brian I., Uemura, Hirotsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732816/
https://www.ncbi.nlm.nih.gov/pubmed/34800178
http://dx.doi.org/10.1007/s10147-021-02014-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732816/
https://www.ncbi.nlm.nih.gov/pubmed/34800178
http://dx.doi.org/10.1007/s10147-021-02014-7

Ejemplares similares